Weight Loss Wellness
Adjust Mental Health is happy to introduce the addition of a structured, evidence-based GLP-1 weight management service for patients with obesity and related metabolic conditions. This program is designed to integrate with our existing psychiatric care model, addressing both physical and mental health outcomes.
Many struggle with comorbid obesity, insulin resistance, and cardiometabolic risk factors. These conditions directly impact psychiatric outcomes, including mood, energy, cognition, and medication response.
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are well-supported by clinical evidence demonstrating meaningful and sustained weight loss, improved glycemic control, and reduction in cardiovascular risk.
Completion of this form does not guarantee eligibility, medical appropriateness, insurance coverage, or prescription approval. A medical evaluation, review of your medical history, and possible lab work may be required before treatment recommendations are made.